Topline Results: Kyowa Kirin’s OX40 Inhibitor Hits it Marks in Phase 3 AD Study
Rocatinlimab, an investigational therapy targeting the OX40 receptor, met its co-primary endpoints in a study of adults with moderate to severe atopic dermatitis (AD), according to top-line data from the Phase 3 ROCKET HORIZON Trial released at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. Co-primary endpoints in this study included achievement of […]